Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
TA remains optimistic about Alpha’s earnings outlook, supported by steady organic growth from its four existing IVF centres. Looking ahead, new centres in Sabah, Johor, Indonesia, and the Philippines are expected to drive future growth. TA maintains its earnings forecasts and reiterates a Buy call with a target price of RM0.42 per share.
